- Details
- Description
-
Packaging Size33c/bottle
-
Strength0.2g
-
CompositonTaletrectinib
-
TreatmentROS1-positive non–small cell lung cancer
-
Formcapsule
-
Brand达伯乐 (BTROZI)
-
Quantity Unit0.2g*33c/box
-
ManufacturerInnovent & Nuvation Bio
Taletrectinib is a potent, orally active, and next-generation selective ROS1/NTRK inhibitor. Taletrectinib potently inhibits recombinant ROS1, NTRK1, NTRK2, and NTRK3 with IC50s of 0.207, 0.622, 2.28, and 0.98 nM, respectively. Taletrectinib also inhibits ROS1 G2032R and other Crizotinib-resistant ROS1 mutants.
The FDA has approved taletrectinib (Ibtrozi) for the treatment of patients with locally advanced or metastatic, ROS1-positive non–small cell lung cancer
《FDA approves taletrectinib for ROS1-positive non-small cell lung cancer》